Quantification of soluble epoxide hydrolase inhibitors in experimental and clinical samples using the nanobody-based ELISA

Yang, Huiyi; Meng, Qing; He, Qiyi; Hwang, Sung Hee; Yang, Jun; McCoy, Mark R.; Morisseau, Christophe; Zhao, Suqing; Hammock, Bruce D.

doi:10.1016/j.jpha.2023.05.006

Cited by 5 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, several methods have been proposed including labeling and label-free analytical techniques. Labeling analysis techniques, such as fluorescence − and radionuclide labeling, , can trace the biodistribution of LNPs in vivo , but are faced with the limitations of inaccuracy, unsafety, and high cost . As a label-free method, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a safe and reliable strategy, which has highly sensitive analysis. , However, it is devastating for the lipid membrane of LNPs when organic reagents are used in the pretreatment of biological samples, which makes it hard to identify drug-loading LNPs. , To date, how to accurately recognize and then sensitively detect intact LNPs (i-LNPs) has hit a breaking point.…”

Section: Introductionmentioning

confidence: 99%

A Dual-Recognition Fluorescence Enzyme-Linked Immunosorbent Assay for Specific Detection of Intact Lipid Nanoparticles via a Localized Scaffolding Autocatalytic DNA Circuit Amplifier

Hu,

Cui,

Zhang

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) are emerging as one of the most promising drug delivery systems. The long-circulating effect of intact LNPs (i-LNPs) is the key to efficacy and toxicity in vivo. However, the significant challenge is specific and sensitive detection of i-LNPs. Herein, a dual-recognition fluorescence enzyme-linked immunosorbent assay (DR-FELISA) was developed to directly isolate and detect i-LNPs by combining dual-recognition separation with a one-step signal amplification strategy. The microplates captured and enriched i-LNPs through antibody−antigen reaction. Dual-chol probes were spontaneously introduced into the lipid bilayer of captured i-LNPs, converting the detection of i-LNPs into the detection of double-cholesterol probes. Finally, the end of the dual-chol probes initiated the localized scaffolding autocatalytic DNA circuits (SADC) system for further signal amplification. The SADC system provides a sensitive and efficient amplifier through localized network structures and self-assembled triggers. Simultaneous recognition of i-LNPs surface PEG-lipid and lipid bilayer structures significantly eliminates interference from biological samples. i-LNPs were detected with high selectivity, ranging from 0.2 to 1.25 mg/mL with a limit of detection of 0.1 mg/ mL. Moreover, this method allows the isolation and quantitative analysis of different formulations of i-LNPs in serum samples with a satisfactory recovery rate ranging from 94.8 to 116.3%. Thus, the DR-FELISA method provides an advanced platform for the exclusive and sensitive detection of i-LNPs, providing new insights for the study of the quality and intracorporal process of complex formulations.

show abstract

Section: Introductionmentioning

confidence: 99%

A Dual-Recognition Fluorescence Enzyme-Linked Immunosorbent Assay for Specific Detection of Intact Lipid Nanoparticles via a Localized Scaffolding Autocatalytic DNA Circuit Amplifier

Hu,

Cui,

Zhang

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

show abstract

Biosensing materials for monoclonal antibody detection: An overview

Zhang,

Fan,

Chai

et al. 2024

Responsive Materials

View full text Add to dashboard Cite

Considering the continuous advances in the synthesis and clinical applications of monoclonal antibodies (mAbs), precision therapies that employ mAbs are essential. In recent years, extensive efforts have been invested in developing novel strategies or technologies for detection of mAbs. Given the availability of advanced biosensing materials, various assemblies of multifunctional materials can be prepared by intelligent design when evaluating targets for mAbs. This article provides an overview of the recent advances and functional applications of biosensing materials for mAb detection. Subsequently, we present the approaches by which mAb receptors are combined with materials to construct stimulus‐responsive analytical platforms that evaluate the contents and activities of mAbs in biological systems, enabling real‐time monitoring and diagnosis that could facilitate administration of mAbs during treatment. Furthermore, the review examines various applications of biosensing for mAb detection and implications in real‐world contexts; it also discusses ongoing challenges and future prospects.

show abstract

Double hook-type aptamer-based colorimetric and electrochemical biosensor enables rapid and robust analysis of EpCAM expression

Hu,

Yang,

Chen

et al. 2024

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Quantification of soluble epoxide hydrolase inhibitors in experimental and clinical samples using the nanobody-based ELISA

Cited by 5 publications

References 35 publications

A Dual-Recognition Fluorescence Enzyme-Linked Immunosorbent Assay for Specific Detection of Intact Lipid Nanoparticles via a Localized Scaffolding Autocatalytic DNA Circuit Amplifier

A Dual-Recognition Fluorescence Enzyme-Linked Immunosorbent Assay for Specific Detection of Intact Lipid Nanoparticles via a Localized Scaffolding Autocatalytic DNA Circuit Amplifier

Biosensing materials for monoclonal antibody detection: An overview

Double hook-type aptamer-based colorimetric and electrochemical biosensor enables rapid and robust analysis of EpCAM expression

Contact Info

Product

Resources

About